Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERASE-C: Micro-elimination of HCV in Hemodialysis Patients
NCT03891550Phase 3Unknown
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
- Start
- May 2019
- Primary completion
- Apr 2024
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of velpatasvir in hepatitis C (HCV), sponsored by Kaohsiung Medical University Chung-Ho Memorial Hospital. Primary endpoint: Rate of HCV micro-elimination in the per-protocol (PP) HD centers at 9 months. Status: unknown.
02
Drugs
velpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03891550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03891550.